Zimbabwe has declined a major US health deal valued at $367m (272 million pounds) spanning five years because of the United States' insistence on sensitive biological samples.
The decision came to light following a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the deal was "skewed".
An official representative later clarified that the United States was demanding access to genetic material for scientific study and commercial purposes but was not willing to guarantee the resulting advantages from any future treatments.
"We are forced to start the difficult and regrettable process of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further dialogue to secure a deal acceptable to all parties so the country's critical HIV programme can be sustained.
Broader Background
This development follows a comparable case in neighbouring Kenya, where a court halted a related deal with the US following concerns were filed about the safety of citizens' medical information.
After resuming office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral agreements to boost openness and accountability.
According to statements, Sixteen African countries have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to share its genetic material and health information indefinitely, with no equivalent guarantee of access to any medical innovations – such as new medicines or tests – that might result from that shared data," Mangwana explained.
"Effectively, our nation would provide the raw materials for medical research with no certainty that the resulting innovations would be accessible to our population if a new health crisis arise."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were disrupting frameworks already set up through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This system is designed to ensure that when a nation contributes its samples, the benefits – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how future collaboration might be structured in a way that respects the sovereignty and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but urged that negotiations should continue since much of the country's HIV programmes were funded by external financing.
"In cases where specific concerns arise, such as those relating to information security or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it commented.
The situation highlights the ongoing tensions between accepting vital foreign assistance and protecting local interests in an increasingly data-driven world.